Monday, November 11, 2019
- 9:00AM-11:00AM
-
Abstract Number: 1083
Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease- 9:00AM-11:00AM
-
Abstract Number: 1209
Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project
Measures Of Healthcare Quality Poster II: Improving Care- 9:00AM-11:00AM
-
Abstract Number: 1423
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study
RA – Treatments Poster II: Established Treatments- 9:00AM-11:00AM
-
Abstract Number: 1375
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1314
Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Osteoarthritis – Clinical Poster I- 9:00AM-11:00AM
-
Abstract Number: 1286
Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis
Muscle Biology, Myositis & Myopathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 1252
Pattern of Arthropathy in Patients with Cystic Fibrosis
Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies- 9:00AM-11:00AM
-
Abstract Number: 1334
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1119
Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry
Health Services Research Poster II – ACR/ARP- 9:00AM-11:00AM
-
Abstract Number: 1340
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures- 9:00AM-11:00AM
-
Abstract Number: 1009
PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster- 9:00AM-11:00AM
-
Abstract Number: 1750
Pediatric Sjögren Syndrome: A Single-Center Experience
Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma- 9:00AM-11:00AM
-
Abstract Number: 1249
Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain
Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies- 9:00AM-11:00AM
-
Abstract Number: 1720
Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome